Lane B R, Ast J C, Hossler P A, Mindell D P, Bartlett M S, Smith J W, Meshnick S R
Department of Epidemiology, University of Michigan, Ann Arbor 48109-2029, USA.
J Infect Dis. 1997 Feb;175(2):482-5. doi: 10.1093/infdis/175.2.482.
Sulfa drugs are widely used in the treatment and prophylaxis of Pneumocystis carinii pneumonia. The nucleotide sequences of the sulfa target enzyme, dihydropteroate synthase (DHPS), differed substantially in human-, rat-, and mouse-derived P. carinii. Sequence variation also existed in the DHPSs from human-derived isolates. Six nucleotide changes were found in 6 human isolates; each was nonsynonymous and resulted in an amino acid change. Several of these changes were in highly conserved regions and are similar to those that cause sulfa resistance in other organisms. These data suggest that the human-derived P. carinii DHPS may be evolving under positive selective pressure from sulfa drugs.
磺胺类药物广泛用于卡氏肺孢子虫肺炎的治疗和预防。磺胺类药物的靶标酶二氢蝶酸合酶(DHPS)的核苷酸序列在人源、大鼠源和小鼠源的卡氏肺孢子虫中存在很大差异。人源分离株的DHPS中也存在序列变异。在6株人源分离株中发现了6个核苷酸变化;每个变化都是非同义的,导致了氨基酸的改变。其中一些变化发生在高度保守的区域,与其他生物体中导致磺胺耐药性的变化相似。这些数据表明,人源卡氏肺孢子虫DHPS可能在磺胺类药物的正选择压力下进化。